Market Intelligence, Structural Challenges, and High-Purity Reagents for Metabolic Oncology and Neurodegeneration Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ATP5MC1 drug discovery. As a highly hydrophobic multipass membrane subunit of the mitochondrial F1Fo ATP synthase, cell-based systems and membrane-mimetic formulations are essential for structural fidelity. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ATP5MC1 Recombinant Protein (Wild-type and Mutant), Sequence Verified, High Purity (>95%), Endotoxin <1EU/ug. Available in detergent-solubilized or Nanodisc formulation retaining native ring-shaped oligomer. | View ATP5MC1 Products |
| Gene Delivery | ATP5MC1 Promise-ORF / Lentivirus Particles. Full-length ORF with mitochondrial targeting sequence (MTS) retained for stable cell line generation and native mitochondrial localization. | View ATP5MC1 Products |
| Benchmark Ab | Anti-ATP5MC1 Recombinant Antibody. Positive control for flow cytometry, IHC, Western blot, and ICC validation. High Purity (>95%). | View ATP5MC1 Products |
| Validator | ATP5MC1 siRNA Set (3 unique sequences). Target-specific 3' UTR region for precise knockdown verification (>85% efficiency) discriminating against paralogs ATP5MC2/3. | View ATP5MC1 Products |
| Related Target: VDAC1 | Voltage-dependent anion channel 1; partner in mPTP complex. | View VDAC1 Products |
| Related Target: PRKAA1 (AMPK) | Upstream metabolic sensor regulating cellular energy homeostasis. | View PRKAA1 Products |
| Related Target: ATP5B | ATP Synthase Subunit Beta (catalytic core); biomarker for complex integrity. | View ATP5B Products |
| Related Target: ATP5O (OSCP) | Stator subunit stabilizing F1-Fo interaction; relevant for PPI disruption assays. | View ATP5O Products |
| Related Target: SLC25A5 | ADP/ATP Translocase 2 (ANT2); synergistic metabolic pathway for ATP transport inhibition. | View SLC25A5 Products |
| Related Target: ATP5F1A | F1 catalytic alpha subunit; core complex partner for holoenzyme functional assays. | View ATP5F1A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Complex Membrane Conformation & Mitochondrial Folding | Lentivirus-mediated stable cell lines with verified N-terminal MTS preserve native OXPHOS architecture. Nanodisc-embedded protein retains correct c-ring oligomeric state. |
| Hydrophobic Membrane Insertion | Detergent-free Nanodisc or DDM-solubilized formats available; maintains ring-shaped oligomeric structure essential for proton channel assays. |
| Isoform Selectivity (ATP5MC1 vs. ATP5MC2/3) | ATP5MC1-specific siRNA targeting 3' UTR differences; mass spectrometry-verified paralog proteins for orthogonal binding assays. |
| Lack of Reliable Controls | High-purity recombinant benchmark antibody and validated siRNA included for assay standardization. |
| Metabolic Assay Variability | Endotoxin Controlled (<1EU/ug) formulations prevent artifactual cellular stress. |
| Compound Aggregation False Positives | Validated siRNA controls included for target-specificity confirmation in HTS counter-assays. |
| Cross-species Toxicology Evaluation | Human / Mouse / Cyno ortholog proteins available with sequence confirmation. |
Live ATP5MC1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The ATP5MC1 subunit represents a paradigm shift in targeting the "undruggable" mitochondrial Fo sector of ATP synthase. As metabolic reprogramming (Warburg effect) drives aggressive cancers, ATP5MC1—the ring-forming proton channel subunit—has emerged as a high-value target for disrupting the proton motive force without affecting glycolytic ATP production. The race for ATP5MC1 therapeutics is intensifying, with major players shifting focus from broad-spectrum metabolic poisons to structure-specific protein-protein interaction (PPI) disruptors and isoform-selective strategies. First-generation direct inhibitors face systemic toxicity challenges, driving next-wave R&D toward localized mitochondrial disruption, mitochondria-targeted degraders (mito-PROTACs), and synthetic lethality combinations in solid tumors. Paralog-selective modulation (ATP5MC1 vs. tissue-specific ATP5MC2/ATP5MC3) is anticipated to become standard to minimize cardiac and neuronal toxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors (including Allosteric Modulators) | AstraZeneca, Mitobridge (Astellas), Calico, AbbVie, Early-stage Biotechs | Solid Tumors, Ischemia-Reperfusion, Metabolic Syndrome | Thermal Shift Assay (correctly folded c-ring oligomer); Nanodisc-embedded protein for biophysical screening; ATPase activity coupled assay with intact F1Fo complex. |
| Targeted Degraders (PROTAC, Mito-PROTAC) | Preclinical Innovators, Academic Spin-offs | Oncology, Metabolic Syndromes | Cell-based degradation assay; high-purity antigens for ternary complex SPR; stable cell lines for degradation kinetics. |
| Gene Silencing (siRNA, shRNA, RNAi) | Alnylam, Silence Therapeutics, Functional Genomics Consortia | Hepatocellular Carcinoma, Chemoresistance Models | Paralog-selective siRNA sets targeting ATP5MC1-specific 3' UTR for specific knockdown validation; lentiviral ORF rescue. |
| Peptide-based PPI Disruptors | Novartis, Academic Consortia | Neurodegeneration, Heart Failure | Surface Plasmon Resonance (SPR) with immobilized full-length protein; Co-IP validation with ATP5B/ATP5O subunits. |